[PDF][PDF] LB745. Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine (RSVPreF3 OA) is efficacious in adults≥ 60 years of age (YOA)
MG Ison, A Papi, JM Langley, DG Lee… - Open Forum …, 2022 - academic.oup.com
Background RSV-associated acute respiratory infections (ARI), particularly lower respiratory
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …
[HTML][HTML] LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults≥ 60 Years of Age (YOA)
MG Ison, A Papi, JM Langley, DG Lee… - Open Forum …, 2022 - ncbi.nlm.nih.gov
Background RSV-associated acute respiratory infections (ARI), particularly lower respiratory
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …
LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults≥ 60 Years of Age (YOA)
MG Ison, A Papi, JM Langley, DG Lee… - Open Forum …, 2022 - academic.oup.com
Background RSV-associated acute respiratory infections (ARI), particularly lower respiratory
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …